Format

Send to

Choose Destination
Expert Rev Vaccines. 2017 Oct;16(10):955-972. doi: 10.1080/14760584.2017.1374182.

Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.

Surenaud M1,2,3, Lacabaratz C1,2,3, Zurawski G1,3,4, Lévy Y1,2,3,5, Lelièvre JD1,2,3,5.

Author information

1
a INSERM, U955 , Créteil , France.
2
b Faculté de médecine , Université Paris Est , Créteil , France.
3
c Vaccine Research Institute (VRI) , Créteil , France.
4
d Baylor Institute for Immunology Research , Dallas , TX , USA.
5
e AP-HP, Hôpital H. Mondor - A. Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses , Créteil , France.

Abstract

Development of a safe, effective and globally affordable Human Immunodeficiency Virus strain 1 (HIV-1) vaccine offers the best hope for future control of the HIV-1 pandemic. However, with the exception of the recent RV144 trial, which elicited a modest level of protection against infection, no vaccine candidate has shown efficacy in preventing HIV-1 infection or in controlling virus replication in humans. There is also a great need for a successful immunotherapeutic vaccine since combination antiretroviral therapy (cART) does not eliminate the reservoir of HIV-infected cells. But to date, no vaccine candidate has proven to significantly alter the natural history of an individual with HIV-1 infection. Areas covered: For over 25 years, the ANRS (France Recherche Nord&Sud Sida-HIV hépatites) has been committed to an original program combining basic science and clinical research developing an epitope-based vaccine strategy to induce a multiepitopic cellular response against HIV-1. This review describes the evolution of concepts, based on strategies using HIV-1 lipopeptides towards the use of dendritic cell (DC) manipulation. Expert commentary: Understanding the crucial role of DCs in immune responses allowed moving from the non-specific administration of HIV-1 sequences with lipopeptides to DC-based vaccines. These DC-targeting strategies should improve HIV-1 vaccine efficacy.

KEYWORDS:

DC-targeting; HIV-1; epitope; immunogenicity; lipopeptide; vaccine

PMID:
28879788
DOI:
10.1080/14760584.2017.1374182
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center